Beste apotheek van Nederland

Table 23:Testosterone: Improvement in Sexual Intercourse Outcomes
Study/patient Characteristics
Intervention Intervention Intervention
Group 1 Group 2 Group 3
Cavallini 2004 Treatment T 160 mg/d
type
oral
Placebo NA NA
Men >60 with Number of
symptoms of patients at
40 45 - -
androgen baseline
decline and
depressed
4 (3–6) 4 (2–5)
mood
Seftel 2004
Hypogonadal
men
(secondary to
aging and
normogonadotrophic)
IIEF
“Intercourse
Satisfaction”
(range 0–15):
Median score
at baseline
(range)
IIEF
“Intercourse
Satisfaction”:
Median score
at end of
therapy (6
months)
Treatment
type
Number of
patients at
baseline
Percentage of
patients
reporting no
intercourse
during
baseline
period
%
Improvement
in frequency
of intercourse
from baseline
at day 30
5 (3–10)
p <0.01 vs.
baseline
T gel 50
mg/d
4 (3–5)
T gel 100
mg/d
Intervention
Group 4
- -
- -
T patch
~25mg/d
Placebo
99 106 102 99
45 47 49 43
+31
Extracted
from graph
p value vs.
placebo
<0.05
p value vs. T
patch
NS
+39
p value vs.
placebo
0.0096
p value vs. T
patch
0.0356
+21
p value vs.
placebo
NS
+24
p value vs. T
gel (50mg/d
or 100mg/d)
< 0.05
p value vs. T
patch
NS
Schiavi 1997
Men with ED
and hypoactive
sexual desire
Treatment
type
Number of
patients at
baseline
T (IM) 200
mg
18
Crossover
study
(Washout
period: 4
weeks)
Placebo
18
Crossover
study
(Washout
period: 4
weeks)
NA
NA
- -
162